Company: SUPN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0001356576-25-000017
Chunk: 105

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 1C
Chunk 105
---
 Pharmaceuticals, Inc. and Ascent Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 to the Company’s Form 10-Q filed on August 6, 2024).10.51**Contingent Value Rights Agreement, dated as of October 28, 2021, by and between Supernus Pharmaceuticals, Inc. and American Stock Transfer & Trust Company, LLC. (incorporated by reference to Index No. (d)(2)* to the Form SC TO-T/A filed on  November 23, 2021, File No.  005-88106).14 *Code of Ethics (incorporated by reference to Exhibit 14 to the Company's Form 8-K filed on December 20, 2024, File No. 001-35518).19 **Policy Statement on Securities Trades by Directors, Officers, and Employees. (incorporated by reference to Exhibit 19 to the Form 10-K filed on February 27, 2024, File No. 001-35518).21 **Subsidiaries of the Registrant.23.1 **Consent of KPMG LLP.31.1 **Certification of Chief Executive Officer.31.2 **Certification of Chief Financial Officer.32.1 **Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 135032.2 **Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 135097**Incentive Compensation Recoupment Policy.101 **The following financial information from the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, formatted in Inline XBRL: (i) Cover Page; (ii) Consolidated Statement of Earnings; (iii) Consolidated Statement of Comprehensive Earnings; (iv) Consolidated Balance Sheets; (v) Consolidated Statements of Equity; (vi) Consolidated Statements of Cash Flows; and (vii) the Notes to Consolidated Financial Statements, tagged in summary and detail.104**The Cover Page of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, formatted in Inline XBRL (included with the Exhibit 101 attachments).

_______________________________________________________________________________ 

†    Confidential treatment requested under 17 C.F.R. §§200.80(b)(4) and 230.406